Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	Phase I:-To evaluate the safety of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects. <br/ > <br/ >Phase II:-To evaluate the immunogenicity of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects compared to placebo.Timepoint: Phase I: Day 0 and Day 84 <br/ >Phase II: Day 0 and Day 224	Phase I:-To evaluate the safety of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects. <br/ > <br/ >Phase II:-To evaluate the immunogenicity of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects compared to placebo.Timepoint: Phase I: Day 0 and Day 84 <br/ >Phase II: Day 0 and Day 224
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
Oct. 26, 2020, 8:29 a.m.	oms	Phase I:-To evaluate the safety of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects. <br/ > <br/ >Phase II:-To evaluate the immunogenicity of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects compared to placebo.Timepoint: Phase I: Day 0 and Day 84 <br/ >Phase II: Day 0 and Day 224	Phase I:-To evaluate the safety of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects. <br/ > <br/ >Phase II:-To evaluate the immunogenicity of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects compared to placebo.Timepoint: Phase I: Day 0 and Day 84 <br/ >Phase II: Day 0 and Day 224